Description

Roivant Sciences: How Its Unique Deal Structure With Pfizer Could Shape Long-Term Value!

Roivant Sciences reported significant clinical progress during its third quarter ended December 31, 2025, notably with positive Phase II results for brepocitinib in cutaneous sarcoidosis, alongside ongoing developments across its broader pipeline. The Phase II study of brepocitinib, a TYK2/JAK1 inhibitor, demonstrated substantial efficacy in treating cutaneous sarcoidosis—a debilitating skin disease with no currently approved therapies. The trial enrolled 31 patients randomized 3:2:2 to high-dose (45 mg), low-dose (15 mg), or placebo over 16 weeks. Brepocitinib at 45 mg showed a placebo-adjusted mean improvement of approximately 22 points on the Cutaneous Sarcoidosis Activity and Morphology Index (CSAMI), well beyond the five-point threshold considered clinically meaningful. All patients in this arm achieved at least a 10-point CSAMI improvement, with 62% reaching a CSAMI score indicative of functional remission. Additional patient-reported outcomes, including Skindex-16 and the King’s Sarcoidosis Questionnaire skin domain, supported these findings, evidencing meaningful symptom relief and quality-of-life improvements.